ALS is a relentlessly progressive and fatal disease, with no curative therapies available to
date. Symptomatic and palliative care, provided in a multidisciplinary context, still remains …

Increasing evidence suggests a role for the immune system in amyotrophic lateral sclerosis
(ALS). To determine the extent of the immune activation in ALS we analyzed the expression …

Patients with amyotrophic lateral sclerosis (ALS) have evidence of chronic inflammation
demonstrated by infiltration of the gray matter by inflammatory macrophages, IL17A-positive …

Neurological dysfunction and motor neuron degeneration in amyotrophic lateral sclerosis
(ALS) is strongly associated with neuroinflammation reflected by activated microglia and …

Two decades after the discovery that 20% of familial amyotrophic lateral sclerosis (ALS)
cases were linked to mutations in the superoxide dismutase-1 (SOD1) gene, a substantial …

Background Innate neuroimmune dysfunction is a pathobiological feature of amyotrophic
lateral sclerosis (ALS). However, links, if any, between disease and adaptive immunity are …

Neurodegenerative disorders are characterized by the selective vulnerability and
progressive loss of discrete neuronal populations. Non-neuronal cells appear to significantly …

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are
neurodegenerative diseases that overlap in their clinical presentation, pathology and …

Objective: The cause of motor neuron death in ALS is incompletely understood. This study
aims to define the potential involvement of nonneuronal immune-inflammatory factors in the …

Objective: To elucidate amyotrophic lateral sclerosis (ALS) biomarkers and potential
mechanisms of disease, we measured immune cell populations in whole blood from a large …